Advertisement
News
Advertisement

Stentys' new CE Mark indications expand its potential PCI footprint

Mon, 07/15/2013 - 10:29am
Mass Device

Stentys lands new indications for its self-apposing stent, now marketable for a patient population that represents 10% of all PCIs in Europe.

Stentys

Regulators in Europe handed Stentys SA (EPA:STNT) expanded indications for its self-apposing stent, opening up new potential patient populations.

The Stentys treatment for acute myocardial infarction can now be used in patients with trickier cases, such as those with tapered, dilated or very large vessels or those with bypass grafts. E.U. healthcare regulators also lifted certain contraindications on the device, such as for chronic total occlusions and left main bifurcations.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading